Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial studies lenalidomide as chemoprevention in treating patients with
high-risk, early stage B-cell chronic lymphocytic leukemia (B-CLL). Chemoprevention is the
use of certain drugs to keep cancer from forming. The use of lenalidomide may slow disease
progression in patients with early stage B-cell chronic lymphocytic leukemia
Phase:
N/A
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
Celgene Corporation National Cancer Institute (NCI)